CONCENTRATION OF APOLIPOPROTEIN B-100 (b-LP, Apo-B100, Apo-LDL) IN UREMIC PATIENTS

Lutfi Zulbeari, Valon Asani, Zamira Bexheti

Abstract

Disorders of lipo/apoprotein metabolism in patients with chronic kidney disease (CKD) begin to appear in the early stages of the disease, before the start of treatment with chronic hemodialysis (HD) and they represent an essential risk factor for premature onset of atherogenic processes. Patients with CKD and who are uremic before starting HD (hemodialysis) which is manifested with a clinical picture of premature atherosclerosis (Ath). Purpose of the work: The work aimed to determine the concentrations of Apolipoprotein B100 (Apo-B100), and lipid profile in uremic patients treated with long-term hemodialysis (HD) as well as their role in the etiology of premature Ath (Atherosclerosis).Materials and methods: In this the cross-sectional study included N0=120 uremic patients (of whom 66 (55%) were males and 54 (45%) were females with an average age of 59,00±10,00) years old treated with long-term HD over 48 months with a frequency of three times per week with sessions lasting 4.5 hours. All patients were treated in the Clinic of Nephrology and HD at the Faculty of Medicine-Skopje. Results: The results obtained present an average value of three consecutive measurements under identical conditions and are presented in tError! Reference source not found.-4.Statistical processing: The statistical methods used in this study were: mean arithmetic mean, standard deviation X±SD, Student's t-test and Mann Whitney U test. For statistical analysis we used the SPSS software package version 17. Conclusion: In conclusion, we can emphasize that the knowledge of due to etiology of lipo/apoproteins in patients with CKD and those with treated with long-term HD can contribute to the prevention of premature Ath, and to the undertaking of preventive measures that would reduce the high incidence of uremic dyslipidemia, thus slowing the development of Ath. It is a fact that multicenter and long-term studies are needed with a larger number of patients that will confirm or deny the role of Apo-B100 polymorphism in patients with CKD as a new independent factor for the development of premature Ath.

Pages: 24 - 30